...
首页> 外文期刊>RSC Advances >Cathepsin B, H and L inhibitors as cell proliferating agents: design, synthesis, computational and pharmacological studies of some novel 2-(2-naphthoyl)-6,6-dimethyl-3-aryl-2,3,6,7-tetrahydrobenzofuran-4(5H)-ones
【24h】

Cathepsin B, H and L inhibitors as cell proliferating agents: design, synthesis, computational and pharmacological studies of some novel 2-(2-naphthoyl)-6,6-dimethyl-3-aryl-2,3,6,7-tetrahydrobenzofuran-4(5H)-ones

机译:组织蛋白酶B,H和L抑制剂作为细胞增殖剂:一些新颖的2-(2-萘酰基)-6,6-二甲基-3-芳基-2,3,6,7-四氢苯并呋喃的设计,合成,计算和药理学研究-4(5h) - 恩斯

获取原文

摘要

Elevated levels of cathepsins B, H and L in disease conditions such as inflammation and cancer accentuate the need for design, synthesis and pharmacological evaluation of new compounds, keeping in view target-specific therapy. The present work describes the one pot multicomponent synthesis of some novel 2-(2-naphthoyl)-6,6-dimethyl-3-aryl-2,3,6,7-tetrahydrobenzofuran-4(5 H )-ones in good yields. The synthesized compounds were analysed by spectral and X-crystallographic studies and have been found to be potential inhibitors to cathepsins B, H and L. The extent of inhibition varied with the substitution. Among the synthesized compounds, nitro-substituted compound 1d has been evaluated as most inhibitory to cathepsin H, however fluoro-substituted compound 1f was the best inhibitor of cathepsin B and cathepsin L. The compounds have been found more selective towards cathepsin L. In vitro inhibition studies correlate well when tested using MTT assay on HepG2 cells, a hepatocellular carcinoma cell line. The results validated by in silico studies performed with iGemDock predicted that among the synthesized compounds, 1d experiences the highest affinity for cathepsin B and H sites, whereas 1f has the highest affinity to cathepsin L.
机译:疾病和癌症等疾病病症中升高的组织蛋白酶B,H和L水平强调了对新化合物的设计,合成和药理学评估的需求,保持靶向靶特异性疗法。本作者描述了一些新的2-(2-萘酰基)-6,6-二甲基-3-芳基-2,3,6,7-四氢苯脲-4(5h) - 稳定产量的罐多组分合成。通过光谱和X结晶研究分析合成化合物,并已发现是对组织蛋白酶B,H和L的潜在抑制剂。抑制程度随替代而变化。在合成化合物中,硝基取代的化合物1d已被评估为大多数抑制作用于组织蛋白酶h,但是氟取代的化合物1f是组织蛋白酶B和组织蛋白酶L的最佳抑制剂。已发现该化合物对组织蛋白酶L.在体外有选择性更具选择性抑制研究在使用MTT测定对HepG2细胞上的MTT测定进行测试时良好相关,肝细胞癌细胞系。在用Igemdock进行的二氧化硅研究中验证的结果预测,在合成化合物中,1D经历了对组织蛋白酶B和H位点的最高亲和力,而1F对组织蛋白酶L具有最高的亲和力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号